Company intelligence / Profile preview

Branhaven Therapeutics

New Haven, Connecticut, United States

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Biohaven is advancing multiple programs showing positive Phase 1 data including IgG depletion >60-70% with BHV-1300, favorable safety/PK for BHV-2100 and BHV-8000, and initiating pivotal trials for BHV-7000 in epilepsy/mood disorders[1][2][6].

Therapeutic areas: NephrologyImmunologyEndocrinologyNeurologyPsychiatryOncology
Modalities: Small moleculeAntibody drug conjugateBispecific antibodyProtein degrader
Industry: Biotech

Partnerships

Pfizer (prior CGRP franchise)Pyramid Biosciences (BHV-1510)Kleo Pharmaceuticals (BHV-1100)

Beyond the preview

Go deeper on Branhaven Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Branhaven Therapeutics.

Explore the full profile